Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 970-977

  Smith, Patrick F ^a,b   Kearney, Brian P ^c   Liaw, Sandra ^c   Cloen, Denise ^b   Bullock, Julie M ^a   Haas, Curtis E ^a,b   Yale, Kitty ^c   Booker, Brent M ^a   Berenson, Charles S ^b   Coakley, Dion F ^c   Flaherty, John F ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b WNY Veterans Affairs Healthcare System   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

Drug interactions; Methadone; Pharmacokinetics; Tenofovir

Indexed keywords

METHADONE; OPIATE; TENOFOVIR DISOPROXIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PUPIL; SCORING SYSTEM; SIDE EFFECT;

ADENINE; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONFIDENCE INTERVALS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; STEREOISOMERISM; SUBSTANCE-RELATED DISORDERS;

EID: 3543083863     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.970.36141     Document Type: Article

References (33)

1. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
2. Centers for Disease Control and Prevention. DHAP, Division of HIV/AIDS Prevention HIV/AIDS surveillance report, midyear edition through June 2001. Atlanta, GA: Centers for Disease Control and Prevention, 2002;13(1):12.
3. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003;114:573-80.
4. Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003;23:29-43.
5. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
6. Jage J. Methadone: pharmacokinetics and pharmacodynamics of an opiate. Anaesthesist 1989;38:159-66.
7. Eap CB, Bourquin M, Martin J, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000;61:47-54.
8. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997;25:1347-53.
9. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-73.
10. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997;117:13-23.
11. Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993;35:30-4.
12. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med 2000;67:429-36.
13. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS clinical trials group 262). J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:435-43.
14. Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000;24:241-8.
15. Lopez ML, Bano MD, Guillen JL. Long-term stability of methadone in clinical plasma samples stored at -20°C. J Anal Toxicol 2002;26:236-8.
16. Gossop M. The development of a short opiate withdrawal scale (SOWS). Addict Behav 1990;15:487-90.
17. Schwartz EL, Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr 1992;5:619-26.
18. Bertschy G, Eap CB, Powell K, Baumann P. Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Ther Drug Monit 1996;18:570-2.
19. Gilead Sciences, Inc. Viread (tenofovir disoproxil fumarate) product information. Foster City, CA; 2002.
20. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-83.
21. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002;11:271-8.
22. Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 1999;13:1004-5.
23. Altice FL, Friedland GH, Cooney EL. Nevirapine-induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999;13:957-62.
24. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 1999;19:471-2.
25. Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001;33:1595-7.
26. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001;51:213-17.
27. Calvo R, Lukas JC, Rodriguez M, Carlos MA, Suarez E. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. Br J Clin Pharmacol 2002;53:212-14.
28. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy 2000;20:93-4.
29. Jimenez-Lerma JM, Iraurgi I. Potential opiate withdrawal syndrome after ritonavir administration in a patient treated with methadone. Rev Clin Esp 1999;199:188-9.
30. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003;37:476-82.
31. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002;34:1143-5.
32. Stevens RC, Rapaport S, Maroldo-Connelly L, Patterson JB, Bertz R. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2003;33:650-1.
33. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. J Acquir Immune Defic Syndr 2001;27:153-60.